Akeso Inc

Akeso Inc is a clinical stage biopharmaceutical company that engages in the discovery, research and development, and commercialisation of pharmaceutical therapies. Akeso Inc was founded in 2019 in Hong Kong. The company is currently headquartered in Hong Kong, although its distribution chains stretch across the world. Akeso Inc is listed on the Hong Kong Stock Exchange (HKEX) under the 9926.HK ticker. It currently has a market capitalisation of 21.96bn HKD and has seen a 52-week range of 23.00 HKD and 38.95 HKD across 2019/2020. With a goal of becoming a global leader in developing, manufacturing, and bringing to market innovative therapeutic antibodies, Akeso Inc has brought to market a number of high-profile pharmaceutical products. This includes AK104, Penpulimab, AK101, and Ebronucimab, all of which are in various stages of clinical trials. Akeso Inc has collaboration and development agreements with Merck, Sino Bipharm, and Dawnrays Pharma, as well as Zhongshan Health Technology Industrial Base Development Co., Ltd. and Torch Development Zone Linhai Industry Park Development Co., Ltd. If you would like to keep track of the Akeso Inc stock price, add the 9926.HK ticker to your eToro trading watchlist. Start receiving instant updates with all the latest news, press releases, and prices as they happen in real time.